This week, Oracle has entered the AI medical scribe race with a new tool that transcribes patient conversations and enters them into electronic medical records. The tool promises to reduce clicks and improve efficiency for doctors by eliminating the need for typing. The company has tested various language models like GPT-4 and Flame 2 to enhance its performance.
A new strain of Monkeypox in the Democratic Republic of the Congo has raised concerns about a potential global outbreak. Health experts and the WHO fear another epidemic like the one that occurred two years ago.
In other healthcare news, Alnylam Pharma has published phase 3 studies of its drug candidate vutrisiran for cardiovascular disease, showing promising results. Formation Bio has raised $372 million in a series D round for AI-based drug development, while Exsilio has secured $82 million in a Series A round for mRNA gene therapy. Novo Nordisk plans to invest $4.1 billion in a new US facility to boost production of its weight loss and diabetes drugs, Ozempic and Wegovy.
Furthermore, a new study suggests that GLP-1 drugs like Ozempic can lead to loss of bone density, but regular exercise can mitigate this effect. The FDA has approved the first menthol flavored vaporizers, and the CDC has warned of a possible outbreak of dengue in the US.
In addition, Forbes reports on Trump’s top billionaire donors, the future of television in Hollywood, and ByteDance’s commitment to TikTok despite potential bans. Other articles cover rural hospital closures, the impact of Ozempic on fertility, and challenges in responding to bird flu outbreaks in US dairy cows.
Article Source
https://www.forbes.com/sites/alexknapp/2024/06/26/innovationrx-oracle-debuts-ai-tool-to-cut-doctors-screen-time-by-50/
